A global multi-center, randomized Phase III trial of Toripalimab in combination with Axitinib versus Pembrolizumab for the first-line treatment of patients with advanced mucosal melanoma (Combination Clinical Trial)
Latest Information Update: 29 Jan 2021
At a glance
- Drugs Axitinib (Primary) ; Toripalimab (Primary) ; Pembrolizumab
- Indications Malignant melanoma; Mucosal disorders
- Focus Therapeutic Use
- 29 Jan 2021 New trial record
- 24 Jan 2021 According to a Shanghai Junshi Biosciences media release, FDA has also approved the Investigational New Drug (IND) application for this trial.